← Leaderboards
Alexander Rialdi
Icahn School Of Medicine At Mount Sinai
$474,516
Attributed
$474,516
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $171.7K · FY2020–23$200K$150K$100K$50K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$474,516 · 2
By mechanism
K99$343,200 · 1
F32$131,316 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Amaia Lujambio$5,368,450
- Ernesto Guccione$11,143,318
- Eric E Schadt$18,256,361
- Panagiotis Roussos$45,081,240
- Nicole Zatorski$182,232
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsValidationKinase InhibitorPersonalized MedicineResistanceTumor MicroenvironmentDrug TargetingIn VivoMalignant Neoplasm Of LiverOrganoidsPrimary Carcinoma Of The Liver CellsBay 54-9085TumorBeta CateninCessation Of LifeDrug ScreeningImmunocompetentIn VitroLibrariesBiopsyMutationNovel TherapeuticsCancer EtiologyBenchmarking
Grant awards (4)
An immunocompetent platform for the characterization and discovery of novel therapeutics for hepatocellular carcinoma$171,720
K99 · FY2023 · CA · contact PI
An immunocompetent platform for the characterization and discovery of novel therapeutics for hepatocellular carcinoma$171,480
K99 · FY2022 · CA · contact PI
A Pharmacogenomic Approach Using Precision Models of Hepatocellular Carcinoma to Identify Novel Therapeutics$66,390
F32 · FY2021 · CA · contact PI
A Pharmacogenomic Approach Using Precision Models of Hepatocellular Carcinoma to Identify Novel Therapeutics$64,926
F32 · FY2020 · CA · contact PI